Extracted Trials
Select a trial for this version to view the audit.
NCT03425643
KEYNOTE-671Spicer JD et al. (2024)
Eligibility Criteria
Inclusion Criteria
Have previously untreated and pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) NSCLC; if male, must agree to use contraception; if female, not pregnant/breastfeeding; have available tumor tissue; ECOG 0-1; adequate organ function; etc.
Exclusion Criteria
NSCLC superior sulcus, large cell neuro-endocrine cancer, sarcomatoid tumor; known pneumonitis requiring steroids; active infection requiring systemic therapy; prior therapy with PD-1/PD-L1; prior anti-cancer therapy for current malignancy; etc.
Bibliographic Info
- Trial Acronym:
- KEYNOTE-671
- First Author:
- Spicer JD
- Year:
- 2024
- PMID:
- 39288781
Patient Baseline
- N (Intervention):
- 397
- N (Control):
- 400
- Median Follow-up:
- 36.6 months
Intervention Details
Experimental Arm
- •
Control Arm
- •